NCT03834948: AO-176 in Multiple Solid Tumor Malignancies

NCT03834948
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients who have received prior anti-PD-1, -PD-L1/2, -CD47, or -CTLA-4 therapy
https://ClinicalTrials.gov/show/NCT03834948

Comments are closed.

Up ↑